Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 13/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134310 | 0.92 | GAA (0.45) | HDAC1EPHX2ADORA3ADORA2AADORA1 | |
| SCHEMBL6135802 | 0.91 | HTT (0.48) | GRM5TP53 | |
| SCHEMBL6134129 | 0.90 | ADORA2A (0.48) | GRM5HDAC1ADORA3ADORA2AADORA1 | |
| SCHEMBL6134147 | 0.89 | KDM4E (0.48) | GRM5HDAC1ADORA3ADORA2AADORA1 | |
| SCHEMBL6134239 | 0.88 | KDM4E (0.51) | ADORA3ADORA2AADORA1 | |
| SCHEMBL6134844 | 0.85 | TP53 (0.36) | GRM5NTRK1TP53NTRK3 | |
| SCHEMBL6133862 | 0.85 | LMNA (0.45) | HDAC1EPHX2ADORA3TP53 | |
| SCHEMBL6133749 | 0.84 | TP53 (0.44) | ADORA3ADORA1TP53 | |
| SCHEMBL6135441 | 0.83 | POLB (0.47) | NTRK1ADORA1TP53 | |
| SCHEMBL6134592 | 0.83 | ADORA1 (0.47) | ADORA3ADORA2AADORA1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | GRM5 270/4885NTRK1 4294/4885HDAC1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.